<DOC>
	<DOCNO>NCT00372697</DOCNO>
	<brief_summary>This study evaluate safety efficacy increase frequency octreotide acetate injection increase dose partially responsive acromegalic patient persistently uncontrolled disease .</brief_summary>
	<brief_title>Efficacy/Safety Octreotide Acetate Patients With Uncontrolled Acromegaly</brief_title>
	<detailed_description />
	<mesh_term>Acromegaly</mesh_term>
	<mesh_term>Octreotide</mesh_term>
	<criteria>Written voluntary inform consent . Patients biochemically document active acromegaly currently receive somatostatinanalogues conventional treatment regimen ( octreotide 30 mg/28 day ; lanreotide 120 mg/28 day ) least 6 month . Patients uncontrolled disease define patient decrease baseline level growth hormone ( GH ) ≥ 50 % treatment somatostatinanalogues conventional regimen ( sandostatin 30 mg/28 day ; lanreotide 120 mg/28 day ) least 6 month . Baseline ( mean 3 sample ) GH level &gt; 2 µg/L . Insulinlike Growth Factor I ( IGFI ) level upper limit normal age gender . Other protocoldefined inclusion/exclusion criterion apply study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>April 2011</verification_date>
	<keyword>acromegaly</keyword>
	<keyword>octreotide acetate</keyword>
	<keyword>partial responder patient</keyword>
</DOC>